Skip to content
2000
image of Tigecycline in the Era of Antibiotic Resistance: A Current Review

Abstract

Tigecycline (TIG) is a broad-spectrum antibiotic of the tetracycline class that evades the resistance mechanisms common to first- and second-generation tetracyclines and is effective against Gram-negative and Gram-positive bacteria, as well as intracellular bacteria. TIG is indicated for the treatment of intra-abdominal, skin, and soft tissue infections in adults, as well as community-acquired bacterial pneumonia. The clinical performance of the TIG has been the subject of discussion since its introduction due to variable safety and efficacy outcomes. Concerns have arisen regarding its association with increased mortality when used in ventilator-associated pneumonia. In addition, resistance to TIG has been reported, driven by various mechanisms such as expulsion by efflux chromosomal pumps, target site modifications, mutations in genes, and enzymatic inactivation. The latter, particularly due to the emergence of multiple TetX monooxygenase variants, is of growing concern. The rise of resistance to last-line antibiotics like TIG presents a significant public health challenge, given the limited therapeutic alternatives available. Therefore, this review analyzes the safety and efficacy reports of TIG, third-generation tetracyclines, documented clinical cases of resistance, and the underlying mechanisms contributing to resistance.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673418555251022111357
2026-01-09
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673418555251022111357
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Pearson J.C. Gillett E. Gadri N.D. Dionne B. Tetracyclines, the old and the new: A narrative review. CMI. Communications 2025 2 1 105059 10.1016/j.cmicom.2025.105059
    [Google Scholar]
  2. Roberts M.C. Schwarz S. Tetracycline and phenicol resistance genes and mechanisms: Importance for agriculture, the environment, and humans. J. Environ. Qual. 2016 45 2 576 592 10.2134/jeq2015.04.0207 27065405
    [Google Scholar]
  3. Balakrishnan A. Chinthala M. Polagani R.K. Vo D.V.N. Removal of tetracycline from wastewater using g-C3N4 based photocatalysts: A review. Environ. Res. 2023 216 Pt 3 114660 10.1016/j.envres.2022.114660 36368373
    [Google Scholar]
  4. Chopra I. Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001 65 2 232 260 10.1128/MMBR.65.2.232‑260.2001 11381101
    [Google Scholar]
  5. Yoon E.J. Jeong S.H. Aminov R. Editorial: Resistance to third-generation tetracyclines. Front. Microbiol. 2023 13 1114660 10.3389/fmicb.2022.1114660 36713182
    [Google Scholar]
  6. Yaghoubi S. Zekiy A.O. Krutova M. Gholami M. Kouhsari E. Sholeh M. Ghafouri Z. Maleki F. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur. J. Clin. Microbiol Infect. Dis. 2022 41 7 1003 1022 10.1007/s10096‑020‑04121‑1 33403565
    [Google Scholar]
  7. Rusu A. Buta E.L. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics 2021 13 12 2085 10.3390/pharmaceutics13122085 34959366
    [Google Scholar]
  8. Wang Z. Li H. The tigecycline resistance mechanisms in Gram-negative bacilli. Front Cell Infect Microbiol 2024 14 1471469 10.3389/fcimb.2024.1471469 39635040
    [Google Scholar]
  9. Aminov R. Acquisition and spread of antimicrobial resistance: A tet(X) case study. Int J Mol Sci 2021 22 8 3905 10.3390/ijms22083905 33918911
    [Google Scholar]
  10. Deng T. Jia Y. Tong Z. Shi J. Wang Z. Liu Y. Bismuth drugs reverse Tet(X)-Conferred tigecycline resistance in Gram-negative bacteria. Microbiol Spectr 2022 10 1 e01578-21 10.1128/spectrum.01578‑21 35138168
    [Google Scholar]
  11. Sun C. Yu Y. Hua X. Resistance mechanisms of tigecycline in Acinetobacter baumannii. Front Cell Infect Microbiol 2023 13 1141490 10.3389/fcimb.2023.1141490 37228666
    [Google Scholar]
  12. Swaminathan S. Kundu P. Tigecycline: Role in the management of cIAI and cSSTI in the indian context. Indian J. Clin. Med. 2020 10 1-2 24 30 10.1177/26339447211067579
    [Google Scholar]
  13. Korczak L. Majewski P. Iwaniuk D. Sacha P. Matulewicz M. Wieczorek P. Majewska P. Wieczorek A. Radziwon P. Tryniszewska E. Molecular mechanisms of tigecycline-resistance among Enterobacterales. Front Cell Infect Microbiol 2024 14 1289396 10.3389/fcimb.2024.1289396 38655285
    [Google Scholar]
  14. Peleg A.Y. Potoski B.A. Rea R. Adams J. Sethi J. Capitano B. Husain S. Kwak E.J. Bhat S.V. Paterson D.L. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J. Antimicrob. Chemother. 2006 59 1 128 131 10.1093/jac/dkl441 17082201
    [Google Scholar]
  15. Gales A.C. Jones R.N. Andrade S.S. Pereira A.S. Sader H.S. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz. J. Infect. Dis. 2005 9 5 348 356 10.1590/S1413‑86702005000500001 16410885
    [Google Scholar]
  16. Spyridaki I. Psaroulaki A. Vranakis I. Tselentis Y. Gikas A. Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics. Antimicrob. Agents Chemother. 2009 53 6 2690 2692 10.1128/AAC.01424‑08 19332671
    [Google Scholar]
  17. Khalili H. Dashti-Khavidaki S. Khaleghi S. Maleki Z. Rasoolinejad M. Evaluation of Tigecycline activity against methicillin-resistante Staphylococcus aureus isolated from biological samples. Iran. J. Pharm. Res. 2010 9 1 61 65 24363708
    [Google Scholar]
  18. Farrell D.J. Sader H.S. Jones R.N. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob. Agents Chemother. 2010 54 6 2735 2737 10.1128/AAC.01774‑09 20368399
    [Google Scholar]
  19. Tsai H.Y. Liao C.H. Chen Y.H. Lu P.L. Huang C.H. Lu C.T. Chuang Y.C. Tsao S.M. Chen Y.S. Liu Y.C. Chen W.Y. Jang T.N. Lin H.C. Chen C.M. Shi Z.Y. Pan S.C. Yang J.L. Kung H.C. Liu C.E. Cheng Y.J. Liu J.W. Sun W. Wang L.S. Ko W.C. Yu K.W. Chiang P.C. Lee M.H. Lee C.M. Hsu G.J. Hsueh P.R. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: Results from the Tigecycline In vitro Surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob. Agents Chemother. 2012 56 6 3402 3405 10.1128/AAC.00533‑12 22491684
    [Google Scholar]
  20. Seiffert S.N. Marschall J. Perreten V. Carattoli A. Furrer H. Endimiani A. Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. Int. J. Antimicrob. Agents 2014 44 3 260 262 10.1016/j.ijantimicag.2014.05.008 25123809
    [Google Scholar]
  21. Theriot C.M. Schumacher C.A. Bassis C.M. Seekatz A.M. Young V.B. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection. Antimicrob. Agents Chemother. 2015 59 3 1596 1604 10.1128/AAC.04296‑14 25547352
    [Google Scholar]
  22. Lee S.M. Kwon H.Y. Im J.H. Baek J.H. Hwang S.S. Kang J.S. Chung M.H. Lee J.S. In vitro activity of tigecycline against Orientia tsutsugamushi. Yonsei Med. J. 2016 57 4 1034 1037 10.3349/ymj.2016.57.4.1034 27189302
    [Google Scholar]
  23. Lee H. Kim H. Seo Y.H. Yong D. Jeong S.H. Lee K. Chong Y. In vitro activity of tigecycline alone and antimicrobial combinations against clinical Neisseria gonorrhoeae isolates. Diagn. Microbiol. Infect. Dis. 2017 87 2 160 162 10.1016/j.diagmicrobio.2016.10.022 27890419
    [Google Scholar]
  24. Blanton L.S. Wilson N.M. Quade B.R. Walker D.H. Susceptibility of Rickettsia rickettsii to Tigecycline in a Cell Culture Assay and Animal Model for Rocky Mountain Spotted Fever. Am. J. Trop. Med. Hyg. 2019 101 5 1091 1095 https://www.ajtmh.org/view/journals/tpmd/101/5/article-p1091.xml 10.4269/ajtmh.19‑0445 31516114
    [Google Scholar]
  25. Saha S. Islam M.M. Mollick M.K.U. Determination of minimum inhibitory concentration (MIC) of tigecycline against Salmonella typhi. J. Ad-din Women Med. College 2023 11 2 15 19 10.3329/jawmc.v11i2.70479
    [Google Scholar]
  26. De Pascale G. Lisi L. Ciotti G.M.P. Vallecoccia M.S. Cutuli S.L. Cascarano L. Gelormini C. Bello G. Montini L. Carelli S. Di Gravio V. Tumbarello M. Sanguinetti M. Navarra P. Antonelli M. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care 2020 10 1 94 10.1186/s13613‑020‑00715‑2 32661791
    [Google Scholar]
  27. Kasbekar N. Tigecycline: A new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm. 2006 63 13 1235 1243 10.2146/ajhp050487 16790575
    [Google Scholar]
  28. Dimopoulos G. Almyroudi M.P. Kapralos I. Apostolopoulou O. Flevari A. Nicolau D.P. Dokoumetzidis A. Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia. Int. J. Antimicrob. Agents 2022 59 1 106487 10.1016/j.ijantimicag.2021.106487 34843925
    [Google Scholar]
  29. Anyanwu M.U. Nwobi O.C. Okpala C.O.R. Ezeonu I.M. Mobile Tigecycline resistance: An emerging health catastrophe requiring urgent one health global intervention. Front. Microbiol. 2022 13 808744 10.3389/fmicb.2022.808744 35979498
    [Google Scholar]
  30. Zhou C.C. Huang F. Zhang J.M. Zhuang Y.G. Population pharmacokinetics of tigecycline: A systematic review. Drug Des. Devel. Ther. 2022 16 1885 1896 10.2147/DDDT.S365512 35747442
    [Google Scholar]
  31. Kounatidis D. Dalamaga M. Grivakou E. Karampela I. Koufopoulos P. Dalopoulos V. Adamidis N. Mylona E. Kaziani A. Vallianou N.G. Third-generation tetracyclines: Current knowledge and therapeutic potential. Biomolecules 2024 14 7 783 10.3390/biom14070783 39062497
    [Google Scholar]
  32. Fang L.X. Chen C. Cui C.Y. Li X.P. Zhang Y. Liao X.P. Sun J. Liu Y.H. Emerging high-level tigecycline resistance: novel tetracycline destructases spread via the mobile Tet(X). BioEssays 2020 42 8 2000014 10.1002/bies.202000014 32567703
    [Google Scholar]
  33. Chen H. Jiang Y. Li M. Sun Y. Cao J. Zhou C. Zhang X. Qu Y. Zhou T. Acquisition of tigecycline resistance by carbapenem-resistant Klebsiella pneumoniae confers collateral hypersensitivity to aminoglycosides. Front. Microbiol. 2021 12 674502 10.3389/fmicb.2021.674502 34276606
    [Google Scholar]
  34. Wang J. Pan Y. Shen J. Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: A systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob. 2017 16 1 24 10.1186/s12941‑017‑0199‑8 28381268
    [Google Scholar]
  35. Zha L. Pan L. Guo J. French N. Villanueva E.V. Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: A systematic review and meta-analysis. Adv. Ther. 2020 37 3 1049 1064 10.1007/s12325‑020‑01235‑y 32006240
    [Google Scholar]
  36. Oliva M.E. Rekha A. Yellin A. Pasternak J. Campos M. Rose G.M. Babinchak T. Ellis-Grosse E.J. Loh E. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect. Dis. 2005 5 1 88 10.1186/1471‑2334‑5‑88 16236177
    [Google Scholar]
  37. Freire A.T. Melnyk V. Kim M.J. Datsenko O. Dzyublik O. Glumcher F. Chuang Y.C. Maroko R.T. Dukart G. Cooper C.A. Korth-Bradley J.M. Dartois N. Gandjini H. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2010 68 2 140 151 10.1016/j.diagmicrobio.2010.05.012 20846586
    [Google Scholar]
  38. Chen Z. Wu J. Zhang Y. Wei J. Leng X. Bi J. Li R. Yan L. Quan Z. Chen X. Yu Y. Wu Z. Liu D. Ma X. Maroko R. Cooper A. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect. Dis. 2010 10 1 217 10.1186/1471‑2334‑10‑217 20663130
    [Google Scholar]
  39. Breedt J. Teras J. Gardovskis J. Maritz F.J. Vaasna T. Ross D.P. Gioud-Paquet M. Dartois N. Ellis-Grosse E.J. Loh E. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 2005 49 11 4658 4666 10.1128/AAC.49.11.4658‑4666.2005 16251309
    [Google Scholar]
  40. Bergallo C. Jasovich A. Teglia O. Oliva M.E. Lentnek A. de Wouters L. Zlocowski J.C. Dukart G. Cooper A. Mallick R. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: Results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 2009 63 1 52 61 10.1016/j.diagmicrobio.2008.09.001 18990531
    [Google Scholar]
  41. Chaari A. Mnif B. Chtara K. Abid L. Charfeddine S. Baccouche N. Bahloul M. Hammami A. Bouaziz M. Efficacy of tigecycline–colistin combination in the treatment of carbapenem-resistant Klebsiella pneumoniae endocarditis. J. Glob. Antimicrob. Resist. 2015 3 3 214 216 10.1016/j.jgar.2015.06.003 27873712
    [Google Scholar]
  42. Perutelli A. Tascini C. Domenici L. Garibaldi S. Baroni C. Cecchi E. Salerno M.G. Safety and efficacy of tigecycline in complicated and uncomplicated pelvic inflammatory disease. Eur. Rev. Med. Pharmacol. Sci. 2018 22 11 3595 3601 29917214
    [Google Scholar]
  43. Kwon Y.S. Levin A. Kasperbauer S.H. Huitt G.A. Daley C.L. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir. Med. 2019 158 89 91 https://www.sciencedirect.com/science/article/pii/S0954611119303087 10.1016/j.rmed.2019.10.006 31622813
    [Google Scholar]
  44. Bai X. Wang Z. Li W. Wang Y. Lou R. Qu X. Fan L. Zhang W. Wu Y. Yan S. Zhang L. Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative Bacterium pneumonia in intensive care units. BMC Infect. Dis. 2023 23 1 830 10.1186/s12879‑023‑08815‑7 38012576
    [Google Scholar]
  45. Gumudavelli S.V. Shelke A. Priya P. Chauhan R. Dhingra S. Comparative efficacy and safety of tigecycline vs colistin for Carbapenem-resistant Enterobacteriaceae (CRE) infections in cancer patients. Clin. Epidemiol. Glob. Health 2025 33 101996
    [Google Scholar]
  46. Ohashi T. Sugiyama N. Watanabe T. Uryu T. Yoshinaga Y. Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance). J. Infect. Chemother. 2022 28 7 866 874 10.1016/j.jiac.2022.03.003 35367148
    [Google Scholar]
  47. Aljedaani H. Thabit A. Eljaaly K. Aljefri D. Alotabi N. Alghamdi L. Alsahafi G. Abuzaid S. Comparison of the efficacy and safety of standard versus high dose tigecycline. Int. J. Infect. Dis. 2022 116 S12 10.1016/j.ijid.2021.12.029
    [Google Scholar]
  48. Pournaras S. Koumaki V. Spanakis N. Gennimata V. Tsakris A. Current perspectives on tigecycline resistance in Enterobacteriaceae: Susceptibility testing issues and mechanisms of resistance. Int. J. Antimicrob. Agents 2016 48 1 11 18 10.1016/j.ijantimicag.2016.04.017 27256586
    [Google Scholar]
  49. Jang S. AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism. BMB Rep. 2023 56 6 326 334 10.5483/BMBRep.2023‑0070 37254571
    [Google Scholar]
  50. Stein G.E. Babinchak T. Tigecycline: an update. Diagn. Microbiol. Infect. Dis. 2013 75 4 331 336 10.1016/j.diagmicrobio.2012.12.004 23357291
    [Google Scholar]
  51. Greer N.D. Tigecycline (Tygacil): The first in the glycylcycline class of antibiotics. Proc. Bayl. Univ. Med. Cent. 2006 19 2 155 161 10.1080/08998280.2006.11928154 16609746
    [Google Scholar]
  52. Izghirean N. Waidacher C. Kittinger C. Chyba M. Koraimann G. Pertschy B. Zarfel G. Effects of ribosomal protein S10 flexible loop mutations on tetracycline and tigecycline susceptibility of Escherichia coli. Front. Microbiol. 2021 12 663835 10.3389/fmicb.2021.663835 34220749
    [Google Scholar]
  53. Lupien A. Gingras H. Leprohon P. Ouellette M. Induced tigecycline resistance in Streptococcus pneumoniae mutants reveals mutations in ribosomal proteins and rRNA. J. Antimicrob. Chemother. 2015 70 11 2973 2980 10.1093/jac/dkv211 26183184
    [Google Scholar]
  54. Villa L. Feudi C. Fortini D. García-Fernández A. Carattoli A. Genomics of KPC-producing Klebsiella pneumoniae sequence type 512 clone highlights the role of RamR and ribosomal S10 protein mutations in conferring tigecycline resistance. Antimicrob. Agents Chemother. 2014 58 3 1707 1712 10.1128/AAC.01803‑13 24379204
    [Google Scholar]
  55. Cattoir V. Isnard C. Cosquer T. Odhiambo A. Bucquet F. Guérin F. Giard J.C. Genomic analysis of reduced susceptibility to tigecycline in Enterococcus faecium. Antimicrob. Agents Chemother. 2015 59 1 239 244 10.1128/AAC.04174‑14 25348531
    [Google Scholar]
  56. Li X. Mu X. Yang Y. Hua X. Yang Q. Wang N. Du X. Ruan Z. Shen X. Yu Y. Rapid emergence of high-level tigecycline resistance in Escherichia coli strains harbouring blaNDM-5 in vivo. Int. J. Antimicrob. Agents 2016 47 4 324 327 10.1016/j.ijantimicag.2016.01.005 26944192
    [Google Scholar]
  57. Yan W.J. Jing N. Wang S.M. Xu J.H. Yuan Y.H. Zhang Q. Li A. Chen L.H. Zhang J.F. Ma B. Ma Q. Li Y. Molecular characterization of carbapenem-resistant Enterobacteriaceae and emergence of tigecycline non-susceptible strains in the Henan province in China: A multicentrer study. J. Med. Microbiol. 2021 70 3 1325 10.1099/jmm.0.001325 33587030
    [Google Scholar]
  58. He F. Shi Q. Fu Y. Xu J. Yu Y. Du X. Tigecycline resistance caused by rpsJ evolution in a 59-year-old male patient infected with KPC-producing Klebsiella pneumoniae during tigecycline treatment. Infect. Genet. Evol. 2018 66 188 191 10.1016/j.meegid.2018.09.025 30268919
    [Google Scholar]
  59. Beabout K. Hammerstrom T.G. Perez A.M. Magalhães B.F. Prater A.G. Clements T.P. Arias C.A. Saxer G. Shamoo Y. The ribosomal S10 protein is a general target for decreased tigecycline susceptibility. Antimicrob. Agents Chemother. 2015 59 9 5561 5566 10.1128/AAC.00547‑15 26124155
    [Google Scholar]
  60. Haim M.S. Di Gregorio S. Galanternik L. Lubovich S. Vázquez M. Bharat A. Zaheer R. Golding G.R. Graham M. Van Domselaar G. Cardona S.T. Mollerach M. First description of rpsJ and mepA mutations associated with tigecycline resistance in Staphylococcus aureus isolated from a cystic fibrosis patient during antibiotic therapy. Int. J. Antimicrob. Agents 2017 50 6 739 741 10.1016/j.ijantimicag.2017.10.003 29038088
    [Google Scholar]
  61. Niebel M. Quick J. Prieto A.M.G. Hill R.L.R. Pike R. Huber D. David M. Hornsey M. Wareham D. Oppenheim B. Woodford N. van Schaik W. Loman N. Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in Enterococcus faecium. Int. J. Antimicrob. Agents 2015 46 5 572 575 10.1016/j.ijantimicag.2015.07.009 26364847
    [Google Scholar]
  62. Dabul A.N.G. Avaca-Crusca J.S. Navais R.B. Merlo T.P. Van Tyne D. Gilmore M.S. Camargo I.L.B.C. Molecular basis for the emergence of a new hospital endemic tigecycline-resistant Enterococcus faecalis ST103 lineage. Infect. Genet. Evol. 2019 67 23 32 10.1016/j.meegid.2018.10.018 30393188
    [Google Scholar]
  63. Jenner L. Starosta A.L. Terry D.S. Mikolajka A. Filonava L. Yusupov M. Blanchard S.C. Wilson D.N. Yusupova G. Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis. Proc. Natl. Acad. Sci. USA 2013 110 10 3812 3816 10.1073/pnas.1216691110 23431179
    [Google Scholar]
  64. Duffey M. Jumde R.P. da Costa R.M.A. Ropponen H.K. Blasco B. Piddock L.J.V. Extending the potency and lifespan of antibiotics: Inhibitors of Gram-negative bacterial efflux pumps. ACS Infect. Dis. 2024 10 5 1458 1482 10.1021/acsinfecdis.4c00091 38661541
    [Google Scholar]
  65. Vargiu A.V. Phan G. Venter H. Broutin I. The structural and functional study of efflux pumps belonging to the RND transporters family from Gram-negative bacteria. Antibiotics 2022 11 4 429 10.3390/antibiotics11040429 35453181
    [Google Scholar]
  66. Marchetti M.L. Errecalde J.O. Mestorino O.N. Resistencia bacteriana a los antimicrobianos ocasionada por bombas de eflujo. Analecta. Vet. 2011 31 2 40 53
    [Google Scholar]
  67. Soto S.M. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence 2013 4 3 223 229 10.4161/viru.23724 23380871
    [Google Scholar]
  68. Novelli M. Bolla J.M. RND efflux pump induction: A Crucial network unveiling adaptive antibiotic resistance mechanisms of Gram-negative bacteria. Antibiotics 2024 13 6 501 10.3390/antibiotics13060501 38927168
    [Google Scholar]
  69. Holden E.R. Webber M.A. MarA, RamA, and SoxS as mediators of the stress response: Survival at a cost. Front. Microbiol. 2020 11 828 10.3389/fmicb.2020.00828 32431683
    [Google Scholar]
  70. Piddock L.J.V. Multidrug-resistance efflux pumps? not just for resistance. Nat. Rev. Microbiol. 2006 4 8 629 636 10.1038/nrmicro1464 16845433
    [Google Scholar]
  71. Du D. Wang-Kan X. Neuberger A. van Veen H.W. Pos K.M. Piddock L.J.V. Luisi B.F. Multidrug efflux pumps: Structure, function and regulation. Nat. Rev. Microbiol. 2018 16 9 523 539 10.1038/s41579‑018‑0048‑6 30002505
    [Google Scholar]
  72. Lorusso A.B. Carrara J.A. Barroso C.D.N. Tuon F.F. Faoro H. Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int. J. Mol. Sci. 2022 23 24 15779 10.3390/ijms232415779 36555423
    [Google Scholar]
  73. Hentschke M. Christner M. Sobottka I. Aepfelbacher M. Rohde H. Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline. Antimicrob. Agents Chemother. 2010 54 3 1319 1322 10.1128/AAC.00993‑09 20028818
    [Google Scholar]
  74. Chirabhundhu N. Luk-In S. Phuadraksa T. Wichit S. Chatsuwan T. Wannigama D.L. Yainoy S. Occurrence and mechanisms of tigecycline resistance in carbapenem- and colistin-resistant Klebsiella pneumoniae in Thailand. Sci. Rep. 2024 14 1 5215 10.1038/s41598‑024‑55705‑2 38433246
    [Google Scholar]
  75. Rosenblum R. Khan E. Gonzalez G. Hasan R. Schneiders T. Genetic regulation of the ramA locus and its expression in clinical isolates of Klebsiella pneumoniae. Int. J. Antimicrob. Agents 2011 38 1 39 45 10.1016/j.ijantimicag.2011.02.012 21514798
    [Google Scholar]
  76. Roy S. Datta S. Viswanathan R. Singh A.K. Basu S. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007–10) and role of an efflux pump in tigecycline non-susceptibility. J. Antimicrob. Chemother. 2013 68 5 1036 1042 10.1093/jac/dks535 23335112
    [Google Scholar]
  77. Sheng Z.K. Hu F. Wang W. Guo Q. Chen Z. Xu X. Zhu D. Wang M. Mechanisms of tigecycline resistance among Klebsiella pneumoniae clinical isolates. Antimicrob. Agents Chemother. 2014 58 11 6982 6985 10.1128/AAC.03808‑14 25182649
    [Google Scholar]
  78. He F. Fu Y. Chen Q. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae. PLoS One 2015 10 3 e0119064 10.1371/journal.pone.0119064 25734903
    [Google Scholar]
  79. Lv L. Wan M. Wang C. Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae. MBio 2020 11 2 e02930-19 10.1128/mBio.02930‑19 32127452
    [Google Scholar]
  80. Wang C-Z. Gao X. Tu J-Y. Jiao Y.X. Deng Y.T. Liu J.H. Multiple copies of mobile tigecycline resistance efflux pump gene cluster tmexC2D2.2-toprJ2 identified in chromosome of Aeromonas spp. Microbiol. Spectr. 2022 10 6 e03468-22 10.1128/spectrum.03468‑22 36354336
    [Google Scholar]
  81. Jin X. Chen Q. Shen F. Jiang Y. Wu X. Hua X. Fu Y. Yu Y. Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin. Emerg. Microbes. Infect. 2021 10 1 1129 1136 10.1080/22221751.2021.1937327 34074225
    [Google Scholar]
  82. Nielsen L.E. Snesrud E.C. Onmus-Leone F. Kwak Y.I. Avilés R. Steele E.D. Sutter D.E. Waterman P.E. Lesho E.P. IS5 nlm integration, a novel mechanism for rapid in vivo emergence of tigecycline nonsusceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2014 58 10 6151 6156 10.1128/AAC.03053‑14 25092708
    [Google Scholar]
  83. Xu H. Zhou Y. Zhai X. Du Z. Wu H. Han Y. Huo C. Chen Y. Emergence and characterization of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae isolates from blood samples of patients in intensive care units in northern China. J. Med. Microbiol. 2016 65 8 751 759 10.1099/jmm.0.000299 27324378
    [Google Scholar]
  84. Sun L. Xu J. He F. Draft genome sequence data of a tigecycline-resistant Enterobacter cloacae ST93 clinical strain isolated from bloodstream infection. Data Brief 2018 21 414 418 10.1016/j.dib.2018.10.004 30364805
    [Google Scholar]
  85. Chiu S-K. Chan M-C. Huang L-Y. Siu L.K. Chang F.Y. Yeh K.M. Tigecycline resistance among carbapenem-resistant Klebsiella Pneumoniae: Clinical characteristics and expression levels of efflux pump genes. PLoS One 2017 12 4 e0175140 10.1371/journal.pone.0175140 28388651
    [Google Scholar]
  86. Wang Q. Zhang P. Zhao D. Jiang Y. Zhao F. Wang Y. Li X. Du X. Yu Y. Emergence of tigecycline resistance in Escherichia coli co-producing MCR-1 and NDM-5 during tigecycline salvage treatment. Infect. Drug Resist. 2018 11 2241 2248 10.2147/IDR.S179618 30519062
    [Google Scholar]
  87. Malinverni J.C. Silhavy T.J. An ABC transport system that maintains lipid asymmetry in the Gram-negative outer membrane. Proc. Natl. Acad. Sci. USA 2009 106 19 8009 8014 10.1073/pnas.0903229106 19383799
    [Google Scholar]
  88. He F. Xu J. Wang J. Chen Q. Hua X. Fu Y. Yu Y. Decreased susceptibility to tigecycline mediated by a mutation in mlaA in Escherichia coli Strains. Antimicrob. Agents Chemother. 2016 60 12 7530 7531 10.1128/AAC.01603‑16 27671071
    [Google Scholar]
  89. Du X. He F. Shi Q. Zhao F. Xu J. Fu Y. Yu Y. The rapid emergence of tigecycline resistance in blaKPC–2 Harboring Klebsiella pneumoniae, as Mediated in vivo by mutation in tetA during tigecycline treatment. Front. Microbiol. 2018 9 648 10.3389/fmicb.2018.00648 29675006
    [Google Scholar]
  90. Grossman T.H. Tetracycline antibiotics and resistance. Cold Spring Harb. Perspect. Med. 2016 6 4 a025387 10.1101/cshperspect.a025387 26989065
    [Google Scholar]
  91. Nguyen F. Starosta A.L. Arenz S. Sohmen D. Dönhöfer A. Wilson D.N. Tetracycline antibiotics and resistance mechanisms. Biol. Chem. 2014 395 5 559 575 10.1515/hsz‑2013‑0292 24497223
    [Google Scholar]
  92. Linkevicius M. Sandegren L. Andersson D.I. Potential of tetracycline resistance proteins to evolve tigecycline resistance. Antimicrob. Agents Chemother. 2016 60 2 789 796 10.1128/AAC.02465‑15 26596936
    [Google Scholar]
  93. Chiu S.K. Huang L.Y. Chen H. Tsai Y.K. Liou C.H. Lin J.C. Siu L.K. Chang F.Y. Yeh K.M. Roles of ramR and tet (A) mutations in conferring tigecycline resistance in carbapenem-resistant Klebsiella pneumoniae clinical isolates. Antimicrob. Agents Chemother. 2017 61 8 391 10.1128/AAC.00391‑17 28533243
    [Google Scholar]
  94. Moore I.F. Hughes D.W. Wright G.D. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 2005 44 35 11829 11835 10.1021/bi0506066 16128584
    [Google Scholar]
  95. Yang W. Moore I.F. Koteva K.P. Bareich D.C. Hughes D.W. Wright G.D. Tet X. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J. Biol. Chem. 2004 279 50 52346 52352 10.1074/jbc.M409573200 15452119
    [Google Scholar]
  96. Ghosh S. LaPara T.M. Sadowsky M.J. Transformation of tetracycline by TetX and its subsequent degradation in a heterologous host. FEMS Microbiol. Ecol. 2015 91 6 26038239 10.1093/femsec/fiv059
    [Google Scholar]
  97. Hassan R.M. Ghaith D.M. Ismail D.K. Zafer M.M. Reduced susceptibility of Enterococcus spp. isolates from Cairo University Hospital to tigecycline: Highlight on the influence of proton pump inhibitors. J. Glob. Antimicrob. Resist. 2018 12 68 72 10.1016/j.jgar.2017.12.005 29274469
    [Google Scholar]
  98. Volkers G. Palm G.J. Weiss M.S. Wright G.D. Hinrichs W. Structural basis for a new tetracycline resistance mechanism relying on the TetX monooxygenase. FEBS Lett. 2011 585 7 1061 1066 10.1016/j.febslet.2011.03.012 21402075
    [Google Scholar]
  99. Yao C. Jin L. Wang Q. Wang M. Wang R. Cai M. Song K. Wang H. Unraveling the evolution and global transmission of high level tigecycline resistance gene tet(X). Environ. Int. 2025 199 109499 10.1016/j.envint.2025.109499 40311233
    [Google Scholar]
  100. Cheng Q. Cheung Y. Liu C. Chan E.W.C. Wong K.Y. Zhang R. Chen S. Functional and phylogenetic analysis of TetX variants to design a new classification system. Commun. Biol. 2022 5 1 522 10.1038/s42003‑022‑03465‑y 35641548
    [Google Scholar]
  101. Cao J. Wang J. Wang Y. Tigecycline resistance tet(X3) gene is going wild. Biosafety and Health 2020 2 1 9 11 10.1016/j.bsheal.2020.01.002
    [Google Scholar]
  102. Deng M. Zhu M.H. Li J.J. Bi S. Sheng Z.K. Hu F.S. Zhang J.J. Chen W. Xue X.W. Sheng J.F. Li L.J. Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob. Agents Chemother. 2014 58 1 297 303 10.1128/AAC.01727‑13 24165187
    [Google Scholar]
  103. Coyne S. Rosenfeld N. Lambert T. Courvalin P. Périchon B. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2010 54 10 4389 4393 10.1128/AAC.00155‑10 20696879
    [Google Scholar]
  104. Leski T.A. Bangura U. Jimmy D.H. Ansumana R. Lizewski S.E. Stenger D.A. Taitt C.R. Vora G.J. Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone. Int. J. Antimicrob. Agents 2013 42 1 83 86 10.1016/j.ijantimicag.2013.04.014 23688520
    [Google Scholar]
  105. He T. Wang R. Liu D. Walsh T.R. Zhang R. Lv Y. Ke Y. Ji Q. Wei R. Liu Z. Shen Y. Wang G. Sun L. Lei L. Lv Z. Li Y. Pang M. Wang L. Sun Q. Fu Y. Song H. Hao Y. Shen Z. Wang S. Chen G. Wu C. Shen J. Wang Y. Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans. Nat. Microbiol. 2019 4 9 1450 1456 10.1038/s41564‑019‑0445‑2 31133751
    [Google Scholar]
  106. Talsma D.T. Monteiro R. Flores-Vallejo R.C. Heuvelmans M. Le T.N. Hendrickx A.P.A. Rosema S. Maat I. van Dijl J.M. Bathoorn E. Nosocomial transmission of tet(x3), blaNDM-1 and blaOXA-97-carrying Acinetobacter baumannii conferring resistance to eravacycline and omadacycline, the Netherlands, March to August 2021. Euro. Surveill. 2024 29 28 2400019 10.2807/1560‑7917.ES.2024.29.28.2400019 38994602
    [Google Scholar]
  107. Grenier F. Lévesque S. Rodrigue S. Haraoui L-P. Earliest observation of the tetracycline destructase tet(X3 ). Microbiol. Spectr. 2024 12 4 e03327 10.1128/spectrum.03327‑23 38412527
    [Google Scholar]
  108. Chen C. Cui C.Y. Zhang Y. He Q. Wu X.T. Li G. Liao X.P. Kreiswirth B.N. Liu Y.H. Chen L. Sun J. Emergence of mobile tigecycline resistance mechanism in Escherichia coli strains from migratory birds in China. Emerg. Microbes. Infect. 2019 8 1 1219 1222 10.1080/22221751.2019.1653795 31429665
    [Google Scholar]
  109. Marathe N.P. Svanevik C.S. Ghavidel F.Z. Grevskott D.H. First report of mobile tigecycline resistance gene tet(X4)-harbouring multidrug-resistant Escherichia coli from wastewater in Norway. J. Glob. Antimicrob. Resist. 2021 27 37 40 10.1016/j.jgar.2021.07.019 34371242
    [Google Scholar]
  110. Zhai W. Tian Y. Lu M. Liu D. Zhang Y. Presence of mobile tigecycline resistance gene tet (X4) in clinical Klebsiella pneumoniae. Microbiol. Spectr. 2022 10 1 10.1128/spectrum.01081‑21 35138117
    [Google Scholar]
  111. Wang Q. Lei C. Cheng H. Zhang H. Wang H. Widespread dissemination of plasmid-mediated tigecycline resistance gene tet (X4) in Enterobacterales of porcine origin. Microbiol. Spectr. 2022 10 5 e01615-22
    [Google Scholar]
  112. Ma J. Wang J. Yang H. Su M. Li R. Bai L. Feng J. Huang Y. Yang Z. Tang B. IncHI1 plasmids mediated the tet(X4) gene spread in Enterobacteriaceae in porcine. Front. Microbiol. 2023 14 1128905 10.3389/fmicb.2023.1128905 37065147
    [Google Scholar]
  113. Chen T. Zhao M. Tang X. Wang W. Zhang M. Tang J. Wang W. Wei W. Ma B. Zou Y. Zhang N. Mi J. Wang Y. Liao X. Wu Y. Serious risk of Tigecycline resistance in Escherichia coli Isolated from swine manure. Microb. Ecol. 2023 86 2 947 958 10.1007/s00248‑022‑02133‑2 36326874
    [Google Scholar]
  114. Dao T.D. Kasuga I. Hirabayashi A. Nguyen D.T. Tran H.T. Vu H. Pham L.T.N. Vu T.M.H. Hasebe F. Nguyen H.T. Thi T.L. Tran H.H. Shibayama K. Takemura T. Suzuki M. Emergence of mobile tigecycline resistance gene tet(X4)-harbouring Shewanella xiamenensis in a water environment. J. Glob. Antimicrob. Resist. 2022 28 140 142 10.1016/j.jgar.2021.12.022 35021125
    [Google Scholar]
  115. Ding Y. Er S. Tan A. Gounot J.S. Saw W.Y. Tan L.W.L. Teo Y.Y. Nagarajan N. Seedorf H. Comparison of tet (X4)-containing contigs assembled from metagenomic sequencing data with plasmid sequences of isolates from a cohort of healthy subjects. Microbiol. Spectr. 2024 12 4 e03969-23 10.1128/spectrum.03969‑23 38441466
    [Google Scholar]
  116. Fan X.Y. Jiang Y. Wu H. Liu J. Gu Q.Y. Wang Z.Y. Sun L. Jiao X. Li Q. Wang J. Distribution and spread of tigecycline resistance gene tet(X4) in Escherichia coli from different sources. Front. Cell Infect. Microbiol. 2024 14 1399732 10.3389/fcimb.2024.1399732 39006743
    [Google Scholar]
  117. Wang L. Liu D. Lv Y. Cui L. Li Y. Li T. Song H. Hao Y. Shen J. Wang Y. Walsh T.R. Novel plasmid-mediated tet (X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical AAcinetobacter baumannii isolate. Antimicrob. Agents Chemother. 2019 64 1 e01326-19 10.1128/AAC.01326‑19 31611352
    [Google Scholar]
  118. Cheng Y. Li Y. Yang M. He Y. Shi X. Zhang Z. Zhong Y. Zhang Y. Si H. Emergence of novel tigecycline resistance gene tet(X5) variant in multidrug-resistant Acinetobacter indicus of swine farming environments. Vet. Microbiol. 2023 284 109837 10.1016/j.vetmic.2023.109837 37531842
    [Google Scholar]
  119. Liu D. Zhai W. Song H. Fu Y. Schwarz S. He T. Bai L. Wang Y. Walsh T.R. Shen J. Identification of the novel tigecycline resistance gene tet(X6) and its variants in Myroides, Acinetobacter and Proteus of food animal origin. J. Antimicrob. Chemother. 2020 75 6 1428 1431 10.1093/jac/dkaa037 32068864
    [Google Scholar]
  120. Cheng Y. Chen Y. Liu Y. Song J. Chen Y. Shan T. Xiao Y. Zhou K. Detection of a new tet(X6)-encoding plasmid in Acinetobacter towneri. J. Glob. Antimicrob. Resist. 2021 25 132 136 10.1016/j.jgar.2021.03.004 33762210
    [Google Scholar]
  121. He D. Wang L. Zhao S. Liu L. Liu J. Hu G. Pan Y. A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative nlm in a Proteus genomospecies 6 isolate of retail meat origin. J. Antimicrob. Chemother. 2020 75 5 1159 1164 10.1093/jac/dkaa012 32016288
    [Google Scholar]
  122. Soliman A.M. Ramadan H. Zarad H. Sugawara Y. Yu L. Sugai M. Shimamoto T. Hiott L.M. Frye J.G. Jackson C.R. Shimamoto T. Coproduction of Tet(X7) conferring high-level tigecycline Resistance, Fosfomycin FosA4, and Colistin Mcr-1.1 in Escherichia coli strains from chickens in Egypt. Antimicrob. Agents Chemother. 2021 65 6 e02084-20 10.1128/AAC.02084‑20 33820767
    [Google Scholar]
  123. Markley J.L. Wencewicz T.A. Tetracycline-inactivating enzymes. Front. Microbiol. 2018 9 1058 10.3389/fmicb.2018.01058 29899733
    [Google Scholar]
  124. Anthony K.B. Fishman N.O. Linkin D.R. Gasink L.B. Edelstein P.H. Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 2008 46 4 567 570 10.1086/526775 18199038
    [Google Scholar]
  125. Xie J. Wang T. Sun J. Chen S. Cai J. Zhang W. Dong H. Hu S. Zhang D. Wang X. Dong Y. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Int. J. Infect. Dis. 2014 18 62 67 10.1016/j.ijid.2013.09.008 24246741
    [Google Scholar]
  126. Patel J.B. Alby K. Humphries R. Naccache S.N. Simner P.J. Updating breakpoints in the United States: A summary from the ASM clinical microbiology open 2022. J. Clin. Microbiol. 2023 61 10 e01154 10.1128/jcm.01154‑22
    [Google Scholar]
  127. Papadimitriou-Olivgeris M. Bartzavali C. Nikolopoulou A. Kolonitsiou F. Mplani V. Spiliopoulou I. Christofidou M. Fligou F. Marangos M. Impact of Tigecycline’s MIC in the outcome of critically Ill patients with carbapenemase-producing Klebsiella pneumoniae bacteraemia treated with tigecycline monotherapy—validation of 2019′s EUCAST proposed breakpoint changes. Antibiotics 2020 9 11 828 10.3390/antibiotics9110828 33228012
    [Google Scholar]
  128. Moghnieh R.A. Abdallah D.I. Fawaz I.A. Hamandi T. Kassem M. El-Rajab N. Jisr T. Mugharbil A. Droubi N. Al Tabah S. Sinno L. Ziade F. Daoud Z. Ibrahim A. Prescription patterns for Tigecycline in severely Ill patients for Non-FDA approved indications in a developing country: A compromised outcome. Front. Microbiol. 2017 8 497 10.3389/fmicb.2017.00497 28396656
    [Google Scholar]
  129. Schafer J.J. Goff D.A. Stevenson K.B. Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007 27 7 980 987 10.1592/phco.27.7.980 17594203
    [Google Scholar]
  130. Werner G. Gfrörer S. Fleige C. Witte W. Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J. Antimicrob. Chemother. 2008 61 5 1182 1183 10.1093/jac/dkn065 18285315
    [Google Scholar]
  131. Elemam A. Rahimian J. Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis. 2009 49 2 271 274 10.1086/600042 19527172
    [Google Scholar]
  132. Daurel C. Fiant A.L. Brémont S. Courvalin P. Leclercq R. Emergence of an Enterobacter hormaechei strain with reduced susceptibility to tigecycline under tigecycline therapy. Antimicrob. Agents Chemother. 2009 53 11 4953 4954 10.1128/AAC.01592‑08 19738023
    [Google Scholar]
  133. Pfaller M.A. Huband M.D. Streit J.M. Flamm R.K. Sader H.S. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Int. J. Antimicrob. Agents 2018 51 6 848 853 10.1016/j.ijantimicag.2018.01.006 29410368
    [Google Scholar]
  134. Seifert H. Blondeau J. Dowzicky M.J. In vitro activity of tigecycline and comparators (2014–2016) among key WHO ‘priority pathogens’ and longitudinal assessment (2004–2016) of antimicrobial resistance: A report from the T.E.S.T. study. Int. J. Antimicrob. Agents 2018 52 4 474 484 10.1016/j.ijantimicag.2018.07.003 30012439
    [Google Scholar]
  135. Miteu G.D. Achinebiri P. Raghunathan N. Sankaran S. Closing potential drivers of antimicrobial resistance: last-resort antimicrobials with the potential of being misused, the way forward – a short communication. Ann. Med. Surg. (Lond) 2023 85 6 3226 3231 10.1097/MS9.0000000000000760 37363472
    [Google Scholar]
  136. Huemer M. Mairpady Shambat S. Brugger S.D. Zinkernagel A.S. Antibiotic resistance and persistence—Implications for human health and treatment perspectives. EMBO Rep. 2020 21 12 e51034 10.15252/embr.202051034 33400359
    [Google Scholar]
  137. Li F. Xu T. Fang D. Wang Z. Liu Y. Restoring tigecycline efficacy with lysine supplementation in tmexCD-toprJ-positive bacteria. Int. J. Antimicrob. Agents 2025 66 2 107511 10.1016/j.ijantimicag.2025.107511 40246209
    [Google Scholar]
  138. Sun L. Sun L. Li X. Hu X. Wang X. Nie T. Zhang Y. You X. A novel tigecycline adjuvant ML-7 reverses the susceptibility of tigecycline-resistant Klebsiella pneumoniae. Front. Cell Infect. Microbiol. 2022 11 809542 10.3389/fcimb.2021.809542 35071055
    [Google Scholar]
  139. Sun F. Zhang L. Ma X. Ali T. Wu Y. Li L. A promising metabolite, 9-aminominocycline, restores the sensitivity of tigecycline against tet(X4)-positive Escherichia coli. Front. Microbiol. 2024 15 1432320 10.3389/fmicb.2024.1432320 39044954
    [Google Scholar]
  140. Xu L. Zhou Y. Niu S. Liu Z. Zou Y. Yang Y. Feng H. Liu D. Niu X. Deng X. Wang Y. Wang J. A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. EBioMedicine 2022 78 103943 10.1016/j.ebiom.2022.103943 35306337
    [Google Scholar]
  141. Markley J.L. Fang L. Gasparrini A.J. Symister C.T. Kumar H. Tolia N.H. Dantas G. Wencewicz T.A. Semisynthetic analogues of anhydrotetracycline as inhibitors of tetracycline destructase enzymes. ACS Infect. Dis. 2019 5 4 618 633 10.1021/acsinfecdis.8b00349 30835428
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673418555251022111357
Loading
Tigecycline in the Era of Antibiotic Resistance: A Current Review
Bentham Science Publishers ; https://doi.org/10.2174/0109298673418555251022111357
/content/journals/cmc/10.2174/0109298673418555251022111357
/content/journals/cmc/10.2174/0109298673418555251022111357
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Tigecycline ; multidrug resistance ; last resort ; efflux pumps ; Tet(X) ; tetracyclines

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test